-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-508520-36-00
5
2024-09-06
Seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-504330-21-00
1
2024-07-22
advanced/metastatic solid tumors
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-507914-28-00
10
2024-06-19
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
-
2023-503631-18-01
5
2024-05-20
Nervous system diseases
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504899-25-00
5
2024-04-04
Metastatic castration resistant prostate cancer
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2023-505375-75-00
5
2024-04-04
Onset of Atrial Fibrillation and Acute Kidney Injury after coronary ar
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2023-504835-42-00
4
2024-02-29
Heart Failure (Heart Failure with Reduced Ejection Fraction)
-
2022-502415-11-00
5
2023-06-16
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
-
2023-508868-30-00
5
2022-09-26
Treatment of stereotypical prolonged seizure
-
2024-517747-31-00
4
2022-07-22
Depressive disorder comorbid with cancer
-
2024-510950-29-00
5
2022-07-21
Stereotypical prolonged seizure
-
2024-511215-21-00
1
2022-06-07
Metastatic or locally advanced solid tumors for which no standard
ther
-
2024-518243-38-00
5
2022-04-20
Fecal incontinence in female and male patients